Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Benzodiazepine or Classic Psychedelic or [[:Category:Benzisoxazoles|Benzisoxazole]]

Use the filters below to narrow your results.

generic:
brand:
None (78) · Dalmane (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Doral (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Risperdal (oral), Risperdal M-Tab (ODT), Risperdal Consta (biweekly IM LAI), Perseris (monthly SC LAI), Uzedy (monthly/bimonthly SC LAI), Rykindo (biweekly IM LAI) (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) · GABAA positive allosteric modulator (18) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Contains LSA (2) · Contains mescaline (2)
uses:
None (92) · '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"' (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)
starting dose:
None (92) · 0.25 mg (1) · Schizophrenia / mania: 1 mg PO BID, titrate to 4-8 mg/day. Pediatric autism irritability: 0.25-0.5 mg/day, weight-titrated. Consta LAI: 25 mg IM every 2 weeks after oral overlap (1)
preparations:
None (92) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · Tablets 0.25, 0.5, 1, 2, 3, 4 mg; M-Tab ODT 0.5, 1, 2, 3, 4 mg; oral solution 1 mg/mL; Consta LAI 12.5, 25, 37.5, 50 mg; Perseris SC LAI 90, 120 mg monthly (1)
fda max:
None (92) · 10 mg/d (1) · 16 mg/day (schizophrenia, adult); 6 mg/day (bipolar maintenance, autism irritability) (1)
routes:
None (91) · intramuscular (LAI) (1) · Oral (3) · subcutaneous (LAI) (1)
onset:
None (91) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · 30–60 minutes (1) · Neuroleptic effect emerges over days to weeks (1)
duration:
None (91) · 24 hours (oral); 2-4 weeks (LAI formulations) (1) · 6 h (immediate-release); ~11 h (extended-release) (1) · 8–12 hours (1)
halflife:
None (91) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 3–5 hours (1) · Risperidone 3-20 hours; '''9-hydroxy-risperidone (paliperidone) ~20-24 hours''' is the major active metabolite and is separately marketed as a parent compound (Invega)'"`UNIQ--ref-00000021-QINU`"' (1)
bioavailability:
None (91) · 70–90% (oral) (1) · 80-90% oral (1) · ~70% (oral)'"`UNIQ--ref-00000022-QINU`"' (1)
pregnancy:
None (91) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Not established (1) · Signal for neonatal extrapyramidal symptoms and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (91) · Schedule I (United States) (1) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly patients with dementia-related psychosis'"`UNIQ--ref-00000023-QINU`"' (1)

Showing below up to 94 results in range #1 to #94.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"